Sarcopenia – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Sarcopenia – Pipeline Review, H2 2017’, provides an overview of the Sarcopenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sarcopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Sarcopenia

The report reviews pipeline therapeutics for Sarcopenia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Sarcopenia therapeutics and enlists all their major and minor projects

The report assesses Sarcopenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Sarcopenia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Sarcopenia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sarcopenia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

Biophytis SAS

GlaxoSmithKline Plc

Immusoft Corp

MYOS RENS Technology Inc

Neurotune AG

Novartis AG

Regeneron Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

Teijin Pharma Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sarcopenia - Overview

Sarcopenia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Sarcopenia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sarcopenia - Companies Involved in Therapeutics Development

Amgen Inc

Biophytis SAS

GlaxoSmithKline Plc

Immusoft Corp

MYOS RENS Technology Inc

Neurotune AG

Novartis AG

Regeneron Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

Teijin Pharma Ltd

Sarcopenia - Drug Profiles

ARM-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATA-842 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVGN-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimagrumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIO-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Sarcopenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Follistatin for Sarcopenia and Atherosclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEP-28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-1654 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proteins for Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Sarcopenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEISARM-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trevogrumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sarcopenia - Dormant Projects

Sarcopenia - Discontinued Products

Sarcopenia - Product Development Milestones

Featured News & Press Releases

May 11, 2017: BIOPHYTIS: First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia

May 03, 2017: BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and activates muscular metabolism in the SARA-PK clinical trial

Mar 27, 2017: Biophytis opens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study

Mar 21, 2017: BIOPHYTIS to present on BIO101 at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Barcelona

Mar 01, 2017: BIOPHYTIS: Full results of SARA-PK study confirm Sarconeos good pharmacokinetic profile in elderly patients

Dec 16, 2016: Biophytis presents preliminary clinical data of SARA - PK, and new preclinical data of Sarconeos for treating sarcopenia

Nov 29, 2016: BIOPHYTIS Announces Successful Completion of SARA-PK Clinical Study for Sarconeos in Sarcopenia Confirming Safety Profile

Nov 22, 2016: BIOPHYTIS received regulatory authorizations to conduct SARA-OBS study in sarcopenia patients

Nov 15, 2016: BIOPHYTIS Presenting Four Posters on Sarconeos at 9th International Conference on Cachexia, Sarcopenia, and Muscle Wasting

Sep 22, 2016: BIOPHYTIS launches the second phase of Sarconeos pharmacokinetics study (SARA-PK) after successful completion of the initial phase

Aug 26, 2016: BIOPHYTIS: enrollment of the first subjects in the pharmacokinetics study on Sarcopenia

Jul 25, 2016: BIOPHYTIS Receives Belgian Regulatory Authorization to Start Sarconeos Pharmacokinetics Study in Elderly Healthy Volunteers (SARA-PK)

Apr 12, 2016: BIOPHYTIS to Present Key Research Findings on Company Lead Compound at Upcoming Scientific Conferences

Mar 11, 2016: BIOPHYTIS Receives positive Scientific Advice on SARCOB BIO101 Clinical Development Plan from Belgian Regulatory Authority

Nov 26, 2015: Biophytis to present preclinical proof of concept for Sarcob to treat sarcopenic obesity at SCWD on December 4th

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Sarcopenia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Sarcopenia – Pipeline by Amgen Inc, H2 2017

Sarcopenia – Pipeline by Biophytis SAS, H2 2017

Sarcopenia – Pipeline by GlaxoSmithKline Plc, H2 2017

Sarcopenia – Pipeline by Immusoft Corp, H2 2017

Sarcopenia – Pipeline by MYOS RENS Technology Inc, H2 2017

Sarcopenia – Pipeline by Neurotune AG, H2 2017

Sarcopenia – Pipeline by Novartis AG, H2 2017

Sarcopenia – Pipeline by Regeneron Pharmaceuticals Inc, H2 2017

Sarcopenia – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017

Sarcopenia – Pipeline by Teijin Pharma Ltd, H2 2017

Sarcopenia – Dormant Projects, H2 2017

Sarcopenia – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Sarcopenia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports